RECRUITING

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Talk to us

Conditions

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid TumorsKRASNon-small Cell Lung CancerLung CancerColorectal CancerColon CancerMetastatic CancerPancreatic CancerPancreatic Ductal AdenocarcinomaNSCLCCRCPDACPancreatic NeoplasmsCarcinoma, Pancreatic DuctalColorectal NeoplasmsColonic NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsLung NeoplasmsCarcinoma, Non-Small-Cell LungNeoplastic ProcessesThoracic NeoplasmsAntineoplastic AgentsMelanomaGynecological CancersRAS

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Official Title

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Quick Facts

Study Start:2022-05-31
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05379985

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
  2. * Received prior standard therapy appropriate for tumor type and stage
  3. * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  4. * Adequate organ function
  1. * Primary central nervous system (CNS) tumors
  2. * Active, untreated brain metastases
  3. * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
  4. * History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

Contacts and Locations

Study Contact

Revolution Medicines, Inc.
CONTACT
1-844-273-8633
medinfo@revmed.com

Principal Investigator

Revolution Medicines, Inc.
STUDY_DIRECTOR
Revolution Medicines, Inc.

Study Locations (Sites)

UC Irvine/Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
UCLA
Santa Monica, California, 90404
United States
Moffitt Cancer Center
Tampa, Florida, 33612
United States
Johns Hopkins University
Baltimore, Maryland, 21287
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016
United States
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
United States
Columbia University
New York, New York, 10032
United States
Christ Hospital Cancer Center
Cincinnati, Ohio, 45219
United States
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
United States
University of Texas at Austin
Austin, Texas, 78712
United States
Mary Crowley Cancer Research
Dallas, Texas, 75230
United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States
Next Oncology
San Antonio, Texas, 78229
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
United States
Next Oncology Virginia
Fairfax, Virginia, 22031
United States

Collaborators and Investigators

Sponsor: Revolution Medicines, Inc.

  • Revolution Medicines, Inc., STUDY_DIRECTOR, Revolution Medicines, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-31
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2022-05-31
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • KRAS
  • Non-small Cell Lung Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Colon Cancer
  • Metastatic Cancer
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
  • NSCLC
  • CRC
  • PDAC
  • Pancreatic Neoplasms
  • Carcinoma, Pancreatic Ductal
  • Colorectal Neoplasms
  • Colonic Neoplasms
  • Intestinal Neoplasms
  • Gastrointestinal Neoplasms
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Neoplastic Processes
  • Thoracic Neoplasms
  • Antineoplastic Agents
  • Melanoma
  • Gynecological Cancers
  • RAS

Additional Relevant MeSH Terms

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Advanced Solid Tumors